Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Bevacizumab × Breast × Clear all

Phase

Phase 2 116 Phase 3 24 Phase 1 18 Phase 1/2 12 Phase 4 5 Phase NA 3 Phase EARLY_PHASE1 3 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 16 Thoracic 5 Gynecologic 3 CNS 3 NET 1 Head & Neck 1 Endocrine 1 Breast 1

Conditions

Inflammatory Breast Neoplasms 1 Carcinoma, Ductal, Breast 1

Interventions

Capecitabine 14 Paclitaxel 13 Docetaxel 11 Cyclophosphamide 10 Epirubicin 8 Carboplatin 8 Trastuzumab 7 Letrozole 6 Gemcitabine 6 Doxorubicin 6 pertuzumab 5 exemestane 3 Vinorelbine 3 Lapatinib 3 Cisplatin 3 AC protocol 3 pyrotinib 2 palbociclib 2 Zoledronic Acid 2 Thiotepa 2 Taxes 2 Tamoxifen 2 Neoadjuvant Therapy 2 Melatonin 2 Fulvestrant 2 Fluorouracil 2 Exercise 2 Drug Therapy 2 Albumin-Bound Paclitaxel 2 Ado-Trastuzumab Emtansine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01426880 2016-02-15

GeparSixto

GBG Forschungs GmbH

Phase 2/3 Completed

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡